Association between bisphosphonates and jaw osteonecrosis: A study in Wistar rats

Head and Neck

Volumn 33, Issue 2, 2011, Pages 199-207

  Maahs, Marcia P ^a   Azambuja, Alan A ^a   Campos, Maria M ^a   Salum, Fernanda G ^a   Cherubini, Karen ^a  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

alendronate; angiogenesis; bisphosphonates; jaw osteonecrosis; zoledronic acid

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; NITROGEN; VASCULOTROPIN; ZOLEDRONIC ACID;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BONE; BONE NECROSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG INDUCED DISEASE; DRUG USE; FEMALE; HISTOLOGY; INFLAMMATORY INFILTRATE; JAW OSTEONECROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; REPEATED DRUG DOSE; TOOTH EXTRACTION; WISTAR RAT;

ALENDRONATE; ANIMALS; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; IMIDAZOLES; JAW; OSTEONECROSIS; RANDOM ALLOCATION; RATS; RATS, WISTAR; TOOTH EXTRACTION;

EID: 78751477697     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21422     Document Type: Article

References (55)

1. Fleisch H,. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19: 80-100.
2. Fleisch H,. Bisphosphonates-history and experimental basis. Bone 1987; 8 Suppl 1: S23-28.
3. Vasikaran SD,. Bisphosphonates: an overview with special reference to alendronate. Ann Clin Biochem 2001; 38 (Pt 6): 608-623.
4. Carter G, Goss AN, Doecke C,. Bisphosphonates and avascular necrosis of the jaw: a possible association. Med J Aust 2005; 182: 413-415.
5. Marx RE,. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61: 1115-1117.
6. Mortensen M, Lawson W, Montazem A,. Osteonecrosis of the jaw associated with bisphosphonate use: presentation of seven cases and literature review. Laryngoscope 2007; 117: 30-34.
7. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL,. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62: 527-534.
8. Pastor-Zuazaga D, Garatea-Crelgo J, Martino-Gorbea R, Etayo-Pérez A, Sebastián-López C,. Osteonecrosis of the jaws and bisphosphonates. Report of three cases. [Article in English, Spanish] Med Oral Patol Oral Cir Bucal 2006; 11: E76-79.
9. Marx RE, Sawatari Y, Fortin M, Broumand V,. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005; 63: 1567-1575.
10. Migliorati CA,. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 2003; 21: 4253-4254.
11. Migliorati CA, Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB,. Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper. J Am Dent Assoc 2005; 136: 1658-1668.
12. Purcell PM, Boyd IW,. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 2005; 182: 417-418.
13. Farrugia MC, Summerlin DJ, Krowiak E, et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006; 116: 115-120.
14. Schwartz HC,. Osteonecrosis of the jaws: a complication of cancer chemotherapy. Head Neck Surg 1982; 4: 251-253.
15. Tarassoff P, Csermak K,. Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 2003; 61: 1238-1239.
16. Novartis Oncology Medical Affairs & Services. Dear doctor [letter]. 2004. Available at:.
17. Lehman RA Jr, Kuklo TR, Freedman BA, Cowart JR, Mense MG, Riew KD,. The effect of alendronate sodium on spinal fusion: a rabbit model. Spine J 2004; 4: 36-43.
18. Macerata R,. Zometa (zoledronic acid)-intravenous formulation. Investigator's brochure for consultation. 8th ed. 2002.
19. Gratton JP, Rae GA, Claing A, Télémaque S, D'Orléans-Juste P,. Different pressor and bronchoconstrictor properties of human big-endothelin-1, 2 (1-38) and 3 in ketamine/xylazine- anaesthetized guinea-pigs. Br J Pharmacol 1995; 114: 720-726.
20. Waynforth HB, Flecknell PA,. Anaesthesia and postoperative care. In:, Waynforth HB, Flecknell PA, editors. Experimental and surgical technique in the rat. 2nd ed. London: Academic Press; 1992. pp 100-125.
21. Close B, Banister K, Baumans V, et al. Recommendations for euthanasia of experimental animals: Part 1. DGXI of the European Commission. Lab Anim 1996; 30: 293-316.
22. Close B, Banister K, Baumans V, et al. Recommendations for euthanasia of experimental animals: Part 2. DGXT of the European Commission. Lab Anim 1997; 31: 1-32.
23. Landesberg R, Cozin M, Cremers S, et al. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008; 66: 839-847.
24. Diego R, D'Orto O, Pagani D, et al. Bisphosphonate-associated osteonecrosis of the jaws: a therapeutic dilemma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 103: e1-5.
25. Dimitrakopoulos I, Magopoulos C, Karakasis D,. Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int J Oral Maxillofac Surg 2006; 35: 588-593.
26. Wallace JL, Dicay M, McKnight W, Bastaki S, Blank MA,. N-bisphosphonates cause gastric epithelial injury independent of effects on the microcirculation. Aliment Pharmacol Ther 1999; 13: 1675-1682.
27. Nase JB, Suzuki JB,. Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc 2006; 137: 1115-1119; quiz 1169-1170.
28. Gertz BJ, Kline WF, Matuszewski BK, Sacco JF, Lasseter KC, Porras AG,. Oral bioavailability and dose proportionality of alendronate (aminohydroxylbutylidene bisphosphonate) in postmenopausal women. J Bone Miner Res 1991; 6 (Suppl 1): S281.
29. Lin JH, Duggan DE, Chen IW, Ellsworth RL,. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. Drug Metab Dispos 1991; 19: 926-932.
30. Reszka AA,. Mechanisms of action of bisphosphonates. In:, Moral JAR, Macías JG, editors. Practical manual of osteoporosis and mineral metabolism diseases. Madrid: Jarpyo; 2004. pp 175-181.
31. Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 1055-1061.
32. Advisory Task Force on Bisphosphonate-Related Osteonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007; 65: 369-376.
33. Greaves P, Williams A, Eve M,. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 2004; 3: 226-236.
34. Morris TH,. Dose estimation among species. In:, Leary SL, editor. Formulary for laboratory animals. 2nd ed. Iowa, IA: Ames; 1999. pp 3-14.
35. Huang RC, Khan SN, Sandhu HS, et al. Alendronate inhibits spine fusion in a rat model. Spine 2005; 30: 2516-2522.
36. Agarwala S, Sule A, Pai BU, Joshi VR,. Alendronate in the treatment of avascular necrosis of the hip. Rheumatology (Oxford) 2002; 41: 346-347.
37. Hellstein JW, Marek CL,. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005; 63: 682-689.
38. Van den Wyngaert T, Huizing MT, Vermorken JB,. Bisphosphonates and osteonecrosis of the jaw: cause and effect or a post hoc fallacy? Ann Oncol 2006; 17: 1197-1204.
39. Bagan JV, Murillo J, Jimenez Y, et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 2005; 34: 120-123.
40. Fernandes C, Leite RS, LanÃas FM,. Bisphosphonates: synthesis, chemical analysis and pharmacological applications. Quím Nova 2005; 28: 274-280.
41. Leon A, Liu L, Yang Y, et al. Isoprenoid biosynthesis as a drug target: bisphosphonate inhibition of Escherichia coli K12 growth and synergistic effects of fosmidomycin. J Med Chem 2006; 49: 7331-7341.
42. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-6544.
43. Kapitola J, Zák J, Lacinová Z, Justová V,. Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res 2000; 49 Suppl 1: S101-106.
44. Hashimoto K, Morishige K, Sawada K, et al. Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun 2007; 354: 478-484.
45. Fleisch H,. Development of bisphosphonates. Breast Cancer Res 2002; 4: 30-34.
46. Sivakumar B, Harry LE, Paleolog EM,. Modulating angiogenesis: more vs less. JAMA 2004; 292: 972-977.
47. Calixto RF, Teófilo JM, Brentegani LG, Carvalho TL,. Implantation of flakes of castor oil resin in rat dental alveolus. [Article in Portuguese] Pesqui Odontol Bras 2001; 15: 257-262.
48. Zied IC, Milanezi LA, Okamoto T, Okamoto R,. A histological study of alveolar wound healing in rats after extraction and hydrogen peroxide gauze compression. Rev Odontol AraÃatuba 2005; 26: 9-13.
49. Santini D, Vincenzi B, Avvisati G, et al. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients. Clin Cancer Res 2002; 8: 1080-1084.
50. Santini D, Vincenzi B, Dicuonzo G, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 2893-2897.
51. Pampu AA, Dolanmaz D, Tüz HH, Avunduk MC, Kisnisci RS,. Histomorphometric evaluation of the effects of zoledronic acid on mandibular distraction osteogenesis in rabbits. J Oral Maxillofac Surg 2008; 66: 905-910.
52. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J,. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin Cancer Res 2003; 9: 5339-5345.
53. Shweiki D, Itin A, Soffer D, Keshet E,. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
54. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E,. Selective ablation of immature blood vessels in established human tumor s follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-165.
55. Ottewell PD, Mönkkönen H, Jones M, Lefley DV, Coleman RE, Holen I,. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008; 100: 1167-1178.